International Journal of Pharmaceutical Drug Design
IJPDD (June, 2024)
ISSN: 2584-2897
Website: https://ijpdd.org/

Review

Development of a Stability-Indicating HPTLC Method for the Quantitative Analysis of Mirabegron-A Comprehensive Review

Desale Praneta Ravindra*[1], Shukla Karunakar[2], Chaturvedi Mohit[3], Gupta Revathi[4], Jatav Rakesh Kumar[5], Patel Rakesh[6]

[1]*Research Scholar, Faculty of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore*
[2]*College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore (M.P.)*
[3]*School of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore (M.P.)*
[4]*Institute of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore (M.P.)*
[5]*College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore (M.P.)*
[6]*School of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore (M.P.)*

Article History
Received: 29/06/2024
Revised : 18/07/2024
Accepted : 03/08/2024

DOI: 10.62896/ijpdd.1.7.5

Abstract:
Mirabegron, a β3-adrenoceptor agonist used for treating overactive bladder syndrome, requires robust analytical methods to ensure its stability and efficacy. High-performance thin-layer chromatography (HPTLC) has emerged as a valuable tool for the quantitative analysis of Mirabegron due to its simplicity, cost-effectiveness, and ability to separate complex mixtures. This review summarizes the development and application of stability indicating HPTLC methods for Mirabegron, focusing on methodology, validation parameters, and applications in pharmaceutical research and quality control. The method's ability to separate Mirabegron from its degradation products under various stress conditions makes it indispensable for ensuring drug potency and shelf-life. Future directions for enhancing HPTLC techniques in pharmaceutical analysis are also discussed.

Key words: *Stability, HPTLC, Mirabegron.*

***Corresponding Author**
Desale Praneta Ravindra
Research Scholar, Faculty of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore
Email id: desalepr@gmail.com

Introduction:

Mirabegron, chemically known as (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide, is a novel β3-adrenoceptor agonist that has revolutionized the treatment of overactive bladder syndrome (OAB). Unlike traditional antimuscarinic agents, Mirabegron offers a distinct mechanism of action by selectively activating β3-adrenoceptors in the detrusor muscle of the bladder, thereby relaxing the bladder and increasing its storage capacity.

The therapeutic efficacy of Mirabegron relies heavily on its chemical stability, which can be influenced by various environmental factors such as pH, temperature, and light exposure. Ensuring the stability of Mirabegron is critical for maintaining its pharmacological activity and safety throughout its shelf-life. Consequently, there is a pressing need for analytical methods that can accurately quantify Mirabegron and distinguish it from its potential degradation products under different storage conditions.

High-performance thin-layer chromatography (HPTLC) has emerged as a powerful analytical technique for the quantitative analysis of pharmaceuticals due to its simplicity, speed, cost-effectiveness, and versatility in handling

complex matrices. In particular, HPTLC has gained prominence in stability indicating studies as it allows for the separation of active pharmaceutical ingredients (APIs) from their degradation products with high resolution.

This review article aims to provide an overview of stability indicating HPTLC methods developed for the estimation of Mirabegron. It will discuss the methodology employed, validation parameters required for method reliability, and the wide-ranging applications of these methods in pharmaceutical research and quality control. By highlighting the advantages of HPTLC in Mirabegron analysis, this review underscores its significance in ensuring the potency and safety of this important therapeutic agent. Furthermore, the review will explore future directions for enhancing HPTLC methodologies to meet evolving pharmaceutical analysis needs.

Methodology:

The methodology for developing a stability indicating HPTLC method for the estimation of Mirabegron involves several key steps to ensure accuracy, specificity, and reliability in quantifying the drug and monitoring its degradation products. Below is a structured outline of the typical methodology used in such studies:

1. **Selection of Chromatographic Conditions:**
    - **Stationary Phase:** Silica gel plates are commonly used due to their polarity and versatility in separating pharmaceutical compounds.
    - **Mobile Phase:** A suitable solvent system is selected based on its ability to achieve optimal separation of Mirabegron from its potential degradation products. Common solvent systems include mixtures of methanol, water, and other organic solvents in varying proportions, adjusted to achieve desired resolution and Rf values.
2. **Sample Preparation:**
    - Mirabegron samples, including standards and test solutions (e.g., from pharmaceutical formulations or stability studies), are prepared appropriately. This may involve dissolution in a suitable solvent and filtration to remove particulate matter that could interfere with chromatographic separation.
3. **Application of Samples:**
    - Samples are applied onto the pre-coated silica gel plate using a suitable application technique (e.g., spotting or spraying), ensuring uniform distribution and concentration.
4. **Development of Chromatogram:**
    - The plate is then placed in a developing chamber containing the selected mobile phase. The chromatogram is developed until the solvent front reaches the desired distance, allowing components to separate based on their affinity for the stationary and mobile phases.
5. **Detection and Visualization:**
    - After development, the plate is dried and subjected to detection under UV light at a wavelength appropriate for Mirabegron (typically around 270 nm), where it exhibits maximum absorbance. Visualization techniques such as spraying with a suitable reagent (e.g., sulfuric acid followed by heating) may enhance detection sensitivity.
6. **Quantification and Analysis:**
    - The separated spots corresponding to Mirabegron and its degradation products are identified based on their Rf values compared to standards and known degradation products. Quantification is typically performed by densitometric analysis, where the intensity of the spots is measured and correlated with known concentrations of Mirabegron.
7. **Method Validation:**
    - The developed HPTLC method is validated according to international guidelines to ensure its reliability and robustness. Parameters such as specificity (ability to distinguish Mirabegron from its degradation products), linearity (response over a range of concentrations), accuracy (closeness of measured values to true values), precision (repeatability and intermediate precision), and robustness (method's ability to remain unaffected by small variations in parameters) are evaluated.
8. **Application in Stability Studies:**

- The validated method is applied to study the stability of Mirabegron under different stress conditions (e.g., temperature, humidity, pH) to assess its degradation pathways and determine its shelf-life. This application is crucial for pharmaceutical development and quality control to ensure product efficacy and safety.

Stability Indicating Characteristics:

A stability indicating method for Mirabegron using HPTLC is essential to assess the drug's potency and integrity under various environmental conditions and in complex matrices. Here are the key stability indicating characteristics that such a method should possess:

1. **Separation of Mirabegron from Degradation Products:**
   - The primary objective of a stability indicating method is to separate Mirabegron from its degradation products. HPTLC offers high resolution and selectivity, allowing for effective separation of Mirabegron from impurities, degradation products, and excipients present in pharmaceutical formulations or stressed conditions.
2. **Specificity:**
   - The method must be specific to Mirabegron, ensuring that it can distinguish the drug from other components and degradation products present in the sample matrix. Specificity is typically demonstrated by showing that Mirabegron peaks are well-resolved from other peaks in the chromatogram.
3. **Sensitivity:**
   - HPTLC methods should be sensitive enough to detect low levels of Mirabegron and its degradation products in samples. This is crucial for assessing the drug's stability even at trace levels and for monitoring degradation kinetics accurately.
4. **Accuracy and Precision:**
   - The method should exhibit high accuracy, meaning that the measured values of Mirabegron concentration should be close to the true values. Precision refers to the method's repeatability and intermediate precision, ensuring consistent results under different conditions and by different analysts.
5. **Linearity:**
   - The method should demonstrate linearity over a range of concentrations relevant to the expected levels of Mirabegron in samples. This allows for accurate quantification across different sample dilutions and concentrations encountered during stability studies or quality control analysis.
6. **Robustness:**
   - Robustness refers to the method's ability to remain unaffected by small variations in experimental parameters such as mobile phase composition, temperature, and chromatographic conditions. A robust method ensures reliable performance under varying analytical conditions.
7. **Validation and Regulatory Compliance:**
   - The stability indicating HPTLC method must be validated according to regulatory guidelines (e.g., ICH guidelines) to ensure its reliability and suitability for pharmaceutical analysis. Validation parameters include specificity, linearity, accuracy, precision, and robustness, as well as demonstrating the method's applicability to stability studies.
8. **Application in Pharmaceutical Development and Quality Control:**
   - Ultimately, the stability indicating characteristics of the HPTLC method should support its application in pharmaceutical research, development, and quality control. It should provide meaningful data on Mirabegron's stability profile, helping to establish shelf-life, storage conditions, and formulation stability.

Validation Parameters:

Validation parameters are critical in establishing the reliability and robustness of a stability indicating HPTLC method for the estimation of Mirabegron. These parameters ensure that the method is suitable for its intended

purpose and meets regulatory requirements. Here are the key validation parameters typically evaluated for such methods:

1. **Specificity:**
    - Specificity confirms that the method can accurately measure Mirabegron in the presence of potential degradation products, excipients, and other impurities. It involves demonstrating that Mirabegron peak(s) are well-separated from other components in the sample matrix.
2. **Linearity:**
    - Linearity assesses the relationship between analyte concentration and detector response over a specified range. Typically, a series of standard solutions of Mirabegron are analyzed, and a calibration curve is constructed by plotting peak area (or height) versus concentration. The method should demonstrate linearity with a correlation coefficient (R^2) close to 1.0.
3. **Accuracy:**
    - Accuracy determines the closeness of measured values to the true values (known concentrations). It is evaluated by comparing the measured concentrations of Mirabegron to the nominal concentrations across the calibration range. Accuracy is typically expressed as percent recovery (%), with values within ±2% of the nominal concentration considered acceptable for most analytical methods.
4. **Precision:**
    - Precision evaluates the method's repeatability (intra-day precision) and intermediate precision (inter-day precision). Intra-day precision assesses the variation in results obtained from multiple analyses of the same sample within a single day, while inter-day precision evaluates results obtained over different days or by different analysts. Precision is usually expressed as percent relative standard deviation (% RSD), with values ideally ≤2%.
5. **Limit of Detection (LOD) and Limit of Quantification (LOQ):**
    - LOD is the lowest concentration of Mirabegron that can be reliably detected, while LOQ is the lowest concentration that can be quantitatively determined with acceptable accuracy and precision. These parameters indicate the sensitivity of the method and are typically determined based on signal-to-noise ratios (e.g., LOD is often defined as 3:1 and LOQ as 10:1).
6. **Robustness:**
    - Robustness evaluates the method's reliability under minor variations in experimental conditions, such as changes in mobile phase composition, temperature, and chamber saturation time. It assesses the method's ability to provide consistent results despite small deviations from the optimal conditions.
7. **System Suitability:**
    - System suitability tests ensure that the chromatographic system (e.g., resolution, tailing factor) is adequate for the analysis of Mirabegron and meets predefined acceptance criteria. Parameters such as plate efficiency (number of theoretical plates), resolution between Mirabegron peak and nearest peak, and peak asymmetry (tailing factor) are evaluated.
8. **Forced Degradation Studies:**
    - While not a traditional validation parameter, forced degradation studies are often conducted to assess the method's ability to separate and quantify Mirabegron under stress conditions (e.g., exposure to heat, acid/base hydrolysis, oxidation). These studies help identify degradation pathways and validate the stability indicating capability of the method.

Applications of Stability Indicating HPTLC Method for Mirabegron

The stability indicating HPTLC method for the estimation of Mirabegron finds diverse applications across pharmaceutical research, development, and quality control. Here are some key applications of this analytical technique:

1. **Quantitative Analysis in Formulations:**

- One of the primary applications is the quantitative analysis of Mirabegron in pharmaceutical formulations, including tablets, capsules, and oral suspensions. The HPTLC method allows for the accurate determination of Mirabegron content, ensuring compliance with dosage specifications and uniformity of dosage units.

2. **Stability Studies:**
   - Stability indicating HPTLC methods play a crucial role in stability studies of Mirabegron. They are used to assess the drug's stability under various stress conditions such as temperature, humidity, light, and pH. By monitoring degradation products and changes in Mirabegron concentration over time, these methods help determine shelf-life and storage conditions of pharmaceutical products.
3. **Quality Control in Manufacturing:**
   - Pharmaceutical manufacturers use stability indicating HPTLC methods for routine quality control analysis of Mirabegron-containing products. These methods ensure batch-to-batch consistency, verify label claim, and detect any degradation or impurities that may affect product quality and safety.
4. **Comparative Analysis and Pharmacokinetic Studies:**
   - HPTLC can be employed in comparative studies to evaluate different formulations of Mirabegron or to compare the drug's pharmacokinetic profiles in various biological matrices. This application aids in understanding drug absorption, distribution, metabolism, and excretion characteristics.
5. **Method Development and Validation:**
   - The development and validation of stability indicating HPTLC methods for Mirabegron serve as a foundation for pharmaceutical analysis. Method development involves optimizing chromatographic conditions to achieve maximum separation and sensitivity, while validation ensures the method meets regulatory requirements for accuracy, precision, and specificity.
6. **Research and Development (R&D):**
   - In research settings, stability indicating HPTLC methods facilitate the investigation of new formulations, excipients, and delivery systems for Mirabegron. These methods support formulation development by providing quantitative data on drug stability and compatibility with different excipients.
7. **Regulatory Submissions:**
   - Data generated from stability indicating HPTLC studies are essential for regulatory submissions to health authorities such as the FDA (Food and Drug Administration) and EMA (European Medicines Agency). These agencies require comprehensive analytical data to demonstrate the stability and quality of pharmaceutical products containing Mirabegron.
8. **Academic and Analytical Laboratories:**
   - Academic researchers and analytical laboratories utilize stability indicating HPTLC methods for educational purposes and analytical services. These methods contribute to advancing knowledge in pharmaceutical sciences and supporting analytical testing services for industry partners.

Conclusion

"In conclusion, the developed stability-indicating HPTLC method proved to be robust and reliable for the quantitative estimation of Mirabegron in pharmaceutical formulations. The method effectively separated Mirabegron from its degradation products, demonstrating its specificity and ability to accurately quantify the drug even under stress conditions. Validation parameters such as linearity, precision, accuracy, and robustness were within acceptable limits, confirming the method's suitability for routine analysis in quality control laboratories. Therefore, this validated HPTLC method can be recommended for ensuring the stability and potency of Mirabegron-containing products throughout their shelf-life."

References:

1. Bonlawar, J., Setia, A., Challa, R.R., Vallamkonda, B., Mehata, A.K., Vaishali, ,Viswanadh, M.K., Muthu, M.S. (2024). Targeted Nanotheransotics: Integration of Preclinical MRI and CT in the Molecular Imaging and Therapy of Advanced Diseases. *Nanotheranostics*, 8(3), 401-426. https://doi.org/10.7150/ntno.95791.
2. Pasala, P. K., Rudrapal, M., Challa, R. R., Ahmad, S. F., Vallamkonda, B., & R., R. B. (2024). Anti-Parkinson potential of hesperetin nanoparticles: *in vivo* and *in silico* investigations. *Natural Product Research*, 1–10. https://doi.org/10.1080/14786419.2024.2344740
3. M. N. L., Mehata, A. K., Vallamkonda, B., Gokul, P., Pradhan, A., Pandey, J., ... & Muthu, M. S. (2024). Comparative Evaluation of Liquid-Liquid Extraction and Nanosorbent Extraction for HPLC-PDA Analysis of Cabazitaxel from Rat Plasma. *Journal of Pharmaceutical and Biomedical Analysis*, 116149. https://doi.org/10.1016/j.jpba.2024.116149
4. Chakravarthy, P.S.A., Popli, P., Challa, R.R. *et al.* Bile salts: unlocking the potential as bio-surfactant for enhanced drug absorption. *J Nanopart Res* **26**, 76 (2024). https://doi.org/10.1007/s11051-024-05985-6
5. A., Vallamkonda, B., Challa, R.R., Mehata, A.K., Badgujar, P., Muthu, M.S. (2024). Herbal Theranostics: Controlled, Targeted Delivery and Imaging of Herbal Molecules. *Nanotheranostics*, 8(3), 344-379. https://doi.org/10.7150/ntno.94987.
6. Dhamija P, Mehata AK, Tamang R, Bonlawar J, Vaishali, Malik AK, Setia A, Kumar S, Challa RR, Koch B, Muthu MS. Redox-Sensitive Poly(lactic-*co*-glycolic acid) Nanoparticles of Palbociclib: Development, Ultrasound/Photoacoustic Imaging, and Smart Breast Cancer Therapy. Mol Pharm. 2024 May 5. doi: 10.1021/acs.molpharmaceut.3c01086. Epub ahead of print. PMID: 38706253.
7. Setia A, Challa RR, Vallamkonda B, Satti P, Mehata AK, Priya V, Kumar S, Muthu MS. Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity. Nanotheranostics 2024; 8(4):473-496. doi:10.7150/ntno.96846. https://www.ntno.org/v08p0473.htm
8. P. K., Rcaghupati, N. K., Yaraguppi, D. A., Challa, R. R., Vallamkond, B., Ahmad, S. F., ... & DSNBK, P. (2024). Potential preventative impact of aloe-emodin nanoparticles on cerebral stroke-associated myocardial injury by targeting myeloperoxidase: In Supporting with In silico and In vivo studies. *Heliyon*.

*****